Analyst picks & changes

Interneuron Pharmaceuticals Inc.

(IPIC)

Jeffrey Kraws of Montgomery Securities maintained a "buy" following publication of a paper in the Journal of Pharmacology and Experimental Therapeutics critical of d-fenfluramine. IPIC